title: [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].
abstract: Faropenem (FRPM) is an only penem antibiotics. Though it has been reported that FRPM had good efficacy (overall efficacy rate: 82.0%) against patients with complicated urinary tract infection, FRPM has not been frequently used for UTI patients. This multicenter clinical study was designed to compare FRPM 300 mg 3 times daily to Levofloxacin (LVFX), which is the standard treatment for patients with UTI, 100 mg 3 times daily for 7 days in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy. A total of 60 patients with significant bacteriuria and pyuria were included in this study. Overall efficacy rate (excellent plus moderate) was achieved in 90.6% (29/32) of patients treated with FRPM versus 82.1% (23/28) of those treated with LVFX. The ratios of eliminated bacteriuria and cleared pyuria were 71.9% and 56.3% of patients treated with FRPM, and 64.3% and 75.0% of those treated with LVFX. These data were not significant difference. In conclusion, FRPM 300 mg 3 times daily is at least as effective as LVFX 100 mg 3 times daily in patients with complicated urinary tract infection.
authors.affiliation: Department of Urology, Kitakyushu Municipal Tobata Hospital.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Muratani
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Iihara
authors.forename: Takehisa
authors.initials: T
authors.lastname: Nishimura
authors.forename: Hisato
authors.initials: H
authors.lastname: Inatomi
authors.forename: Naohiro
authors.initials: N
authors.lastname: Fujimoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yoji
authors.initials: Y
authors.lastname: Yamada
authors.forename: Koichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matsumoto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007769:Lactams; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications*; D001750:Urinary Bladder, Neurogenic / Q000150:complications*; D014552:Urinary Tract Infections / Q000188:drug therapy*; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D007769:Lactams; D047090:beta-Lactams; D064704:Levofloxacin; D015242:Ofloxacin; C107057:fropenem